<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Metab Brain Dis</journal-id><journal-id journal-id-type="iso-abbrev">Metab Brain Dis</journal-id><journal-title-group><journal-title>Metabolic Brain Disease</journal-title></journal-title-group><issn pub-type="ppub">0885-7490</issn><issn pub-type="epub">1573-7365</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39585487</article-id><article-id pub-id-type="pmc">PMC11588952</article-id>
<article-id pub-id-type="publisher-id">1422</article-id><article-id pub-id-type="doi">10.1007/s11011-024-01422-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Metformin effectively alleviates the symptoms of Alzheimer in rats by lowering amyloid &#x003b2; deposition and enhancing the insulin signal</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3850-4258</contrib-id><name><surname>Abosharaf</surname><given-names>Hamed A.</given-names></name><address><email>hamed_biochemistry@science.tanta.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0001-5824-3676</contrib-id><name><surname>Elsonbaty</surname><given-names>Yasmin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9722-3603</contrib-id><name><surname>Tousson</surname><given-names>Ehab</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4015-7542</contrib-id><name><surname>Mohamed</surname><given-names>Tarek M.</given-names></name><address><email>tarek.ali@science.tanta.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/016jp5b92</institution-id><institution-id institution-id-type="GRID">grid.412258.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9477 7793</institution-id><institution>Biochemistry Division, Chemistry Department, Faculty of Science, </institution><institution>Tanta University, </institution></institution-wrap>Tanta, 31527 Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/016jp5b92</institution-id><institution-id institution-id-type="GRID">grid.412258.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9477 7793</institution-id><institution>Zoology Department, Faculty of Science, </institution><institution>Tanta University, </institution></institution-wrap>Tanta, 31527 Egypt </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>40</volume><issue>1</issue><elocation-id>41</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Alzheimer&#x02019;s disease (AD) exhibits distinct biochemical and histopathological attributes, encompassing cellular, neuronal, and oxidative impairment. There is also an abnormal buildup, misfolding and clumping of amyloid &#x003b2; (A&#x003b2;). The present study aimed to explore the influence of the antihyperglycemic agent metformin on rats with AD-like symptoms, while also elucidating the intricate relationship between insulin resistance and AD. The rats were categorized into five groups: a control group, a saline-administered group, a metformin-treated group, AD-model rats, and AD-rats treated with a 200&#x000a0;mg/kg dose of metformin. Cognitive impairment was rated using the classical labyrinth test. Moreover, serum biochemical parameters, encompassing glucose levels, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Glycated hemoglobin (HbA1c), lipid profile, kidney, and liver function, were evaluated. Additionally, oxidative, antioxidant, and neurotransmitter parameters were measured in hippocampus tissues. Also, the A&#x003b2; and insulin receptor substrate 2 (IRS-2) were measured by immunoblotting. Besides hippocampal histopathology, glial fibrillary acidic protein (GFAP) and calretinin immunoreactivity were monitored. The study findings disclosed deficits in memory and learning capabilities among AD rats. Furthermore, AD-afflicted rats exhibited heightened glucose levels, elevated HOMA-IR and HbA1c values, alongside compromised liver, and kidney functions. Additionally, an upsurge in oxidative stress coincided with a notable reduction in the antioxidant system and neurotransmitters activities. The levels of A&#x003b2; deposition increased, while IRS-2 expression subsided, accompanied by alterations in the hippocampal structure and neuronal damage. These changes were paralleled by an intensification in GFAP reactivity and a detracting in calretinin reactivity. Metformin was altogether able to move forward cognitive execution by means of bringing down oxidative stress and A&#x003b2; conglomeration. Furthermore, metformin was able to improve neurotransmitters and insulin signals. AD, glucose impairment, and brain insulin resistance are completely interlinked, and future AD medications may be inspired by diabetic medication.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11011-024-01422-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Amyloid &#x003b2;</kwd><kwd>Insulin resistance</kwd><kwd>Metformin</kwd><kwd>Glucose impairment</kwd></kwd-group><funding-group><award-group><funding-source><institution>Tanta University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">From both a biomedical and neurological perspective, Alzheimer&#x02019;s disease (AD) stands as the foremost cause of dementia, characterized by the presence of amyloid &#x003b2; (A&#x003b2;) plaques and tau neurofibril tangles (Apter et al. <xref ref-type="bibr" rid="CR5">2015</xref>; Knopman et al. <xref ref-type="bibr" rid="CR31">2021</xref>; Uwishema et al. <xref ref-type="bibr" rid="CR68">2022</xref>). While AD is conspicuously coupled with amnestic cognitive symptoms, there are erratic instances where non-amnestic symptoms manifest as well (Knopman et al. <xref ref-type="bibr" rid="CR31">2021</xref>). AD patients may experience a spectrum of cognitive decline, from mild memory impairment to severe difficulties with daily tasks (Jessen et al. <xref ref-type="bibr" rid="CR27">2014</xref>).</p><p id="Par3">Historically, AD was deemed to have a clinical origin, yet it is now unequivocally recognized as being rooted in neurological factors. The etiology of AD is intricately intertwined with various elements, notably metabolic disorders such as diabetes mellitus (Petersen <xref ref-type="bibr" rid="CR53">2018</xref><bold>)</bold>. In the incipient stages of AD, disturbances in glucose with decreased brain glucose utilization have been pinpointed. This may elucidate the two-way liaison between brain insulin resistance and AD (Li et al. <xref ref-type="bibr" rid="CR36">2016</xref>; Shinohara and Sato <xref ref-type="bibr" rid="CR60">2017</xref>; Pilipenko et al. <xref ref-type="bibr" rid="CR54">2020</xref>). Additionally, it has been reported that compromised brain glucose turnover leads to neuroinflammation, further triggering neurodegenerative symptoms by disrupting synaptic plasticity, neuronal viability, and intercellular communication (Zhang et al. <xref ref-type="bibr" rid="CR72">2018</xref>).</p><p id="Par4">Despite the availability of acetylcholinesterase inhibitors, effective treatments for AD remain notably lacking (Rygiel <xref ref-type="bibr" rid="CR57">2016</xref>). In fact, no new medications have obtained approval from regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicine Agency (EMA) (Apter et al. <xref ref-type="bibr" rid="CR5">2015</xref>). Given the outlook for AD and its connection to diabetes, there is considerable interest in antidiabetic medications as potential innovative therapies for AD.</p><p id="Par5">The approved drug metformin, belonging to the class of biguanides and renowned for its antihyperglycemic effects, is currently a cornerstone in the management of type 2 diabetes mellitus (T2DM) (Ferrannini <xref ref-type="bibr" rid="CR17">2014</xref>). Previous investigations have sought to elucidate the antihyperglycemic properties of metformin. One study suggested that metformin effectively reduces blood glucose levels without inducing noteworthy hypoglycemia, achieved through its ability to lessening intestinal glucose absorption, augment peripheral glucose uptake, and worsen the insulin sensitivity (Grzybowska et al. <xref ref-type="bibr" rid="CR22">2011</xref>). Another inquiry highlighted metformin&#x02019;s capacity to activate AMP-activated protein kinase (AMPK), subsequently inhibiting gluconeogenesis (Matthaei and Greten <xref ref-type="bibr" rid="CR42">1991</xref>). Notably, owing to its minimal side effects, metformin has been explored for various other conditions, including cancer (Coyle et al. <xref ref-type="bibr" rid="CR12">2016</xref>), inflammation (Liu et al. <xref ref-type="bibr" rid="CR37">2023</xref>), cardiovascular disease (Benjamin et al. <xref ref-type="bibr" rid="CR7">2017</xref>), osteoarthritis (Lambova <xref ref-type="bibr" rid="CR33">2023</xref>), and dementia (Kumar et al. <xref ref-type="bibr" rid="CR32">2023</xref>) In light of the proposed connection between neurodegenerative and metabolic disorders, particularly insulin resistance, our study, along with others, postulates that metformin could offer a novel mechanism of action in these conditions (Beeri et al. <xref ref-type="bibr" rid="CR6">2008</xref>; Sonnen et al. <xref ref-type="bibr" rid="CR62">2009</xref>). This study seeks to explore the potential of metformin against the symptoms of Alzheimer&#x02019;s disease induced in rats.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Animals</title><p id="Par6">The rats employed in this study were managed and cared for following the research animal guidelines of the Faculty of Science, Tanta University, Egypt, which adheres to the AARIVE guidelines (Kilkenny et al. <xref ref-type="bibr" rid="CR30">2010</xref>) (Official ethical No. IACUC-SCI-TU-0259). Fifty male Wistar rats, weighing between 200 and 220&#x000a0;g and aged 6&#x02013;7 weeks, were procured from the animal and breeding unit at VACSERA in Cairo, Egypt. This age of mice is useful for behavior studies since, up to five months of age, there was a natural decline in behavioral activity, motor activity, and several rearing rats (Sudakov et al. <xref ref-type="bibr" rid="CR63">2021</xref>). Additionally, female mice were not employed in this investigation to eliminate any variability related to the estrous cycle (Deacon <xref ref-type="bibr" rid="CR13">2006</xref>). The rats were maintained at a temperature of 25&#x000a0;&#x000b0;C under a regular day-night cycle and were given free access to food and water. A minimum acclimatization period of one week was provided before commencing the experiment (Kilkenny et al. <xref ref-type="bibr" rid="CR30">2010</xref>; Percie du Sert et al. <xref ref-type="bibr" rid="CR52">2020</xref>).</p></sec></sec><sec id="Sec4"><title>Experimental section</title><sec id="Sec5"><title>Alzheimer&#x02019;s disease initiation in rats</title><p id="Par7">Five distinct groups were established, each comprising 10 rats per cage that were randomly selected. Further, blinding is not included in the current study due to measuring overt mental activity using videos. G1(Normal): represented untreated rats. G2 (Saline): consisted of control rats receiving saline injections throughout the experiment. G3 (Metformin): included control rats treated with a continuous dose of 200&#x000a0;mg/kg metformin (Sigma-Aldrich, USA). G4 (AD model): comprised AD-induced rats that were orally administered 120&#x000a0;mg/kg D-galactose (D-gal) Sigma-Aldrich, USA) and 50&#x000a0;mg/kg of aluminum chloride (AlCl<sub>3</sub>) (ACROS organics, Geel, Belgium) daily for a month, (Mallikarjuna et al. <xref ref-type="bibr" rid="CR40">2016</xref>). G5 (AD&#x02009;+&#x02009;Metformin): involved AD-rats initially subjected to the conditions of G4 and subsequently treated with an oral dose of 200&#x000a0;mg/kg metformin daily for a month (Zhang et al. <xref ref-type="bibr" rid="CR71">2017</xref>). Changes in body mass were recorded, and cognitive impairment, a hallmark of AD, was assessed using the Classic Labyrinth method (Gasmi <xref ref-type="bibr" rid="CR18">2018</xref>; Abosharaf et al. <xref ref-type="bibr" rid="CR1">2024</xref>). At the experiment&#x02019;s conclusion, the rats were euthanized with an intraperitoneal injection of pentobarbital (40&#x000a0;mg/kg), followed by cervical dislocation. Following confirmation of rat death, the brains were extracted, weighed, and hippocampal tissues were collected, with a portion preserved for histopathology and the remainder stored at &#x02212;80&#x000a0;&#x000b0;C for future analysis. The pancreas was harvested, washed with saline buffer, and preserved in 10% formalin for histopathological examination.</p></sec></sec><sec id="Sec6"><title>Serum biochemical measurements</title><p id="Par8">Blood samples were collected from the central retinal vein, and serum was obtained by incubating the whole blood at room temperature for 30&#x000a0;min followed by centrifugation at 1100xg for 15&#x000a0;min. The resulting serum (<italic>n</italic>&#x02009;=&#x02009;10) was used to measure glucose (Cat No. GL13 20), liver function markers (ALT, Cat. No. AL 10 31, and AST, Cat. No. AS 10 61), kidney function markers including urea (Cat. No. UR 21 10) and creatinine (Cat No. CR 12 51), further the levels of cholesterol (Cat. No. CH 12 20), triacylglycerol (Cat. No. TR 20 30), HDL (Cat. No. CH 12 31), LDL (Cat. No. CH 12 31), iron (Cat. No. IR 15 10) and zinc levels (Cat No. Zn 21 20). These measurements were performed according to kit instructions (Bio-diagnostic Inc, Egypt). Additionally, Rat insulin resistance (HOMA-IR) and insulin concentration ELIZA kit was gained from Invitrogen (USA, Cat. No. ERINS).</p></sec><sec id="Sec7"><title>Neurochemical markers assessment</title><p id="Par9">Neurotransmitters including dopamine, acetylcholine, and acetylcholine esterase were quantified (<italic>n</italic>&#x02009;=&#x02009;10) in the hippocampus tissues of all treated rats. Dopamine levels were assessed using a kit from Eagle Bioscience (Cat. No. 50&#x02013;813-97, Amherst, USA), acetylcholine concentration was determined with a rat acetylcholine kit from My BioSource (Cat. No. MBS728879, San Diego, USA), and acetylcholine esterase activity was measured using a rat acetylcholine esterase (AChE) ELISA kit from Elabscience (Cat No. E-EL-R0355, Texas, USA).</p><sec id="Sec8"><title>Quantification of the oxidative/ antioxidative parameters</title><p id="Par10">Oxidative stress was evaluated in the hippocampus of all rats (<italic>n</italic>&#x02009;=&#x02009;10) by measuring malonaldehyde (MDA) levels, as previously described (Niehaus Jr and Samuelsson <xref ref-type="bibr" rid="CR47">1968</xref>) (Detailed method listed in supporting data). Antioxidant factors including glutathione, superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) were determined using appropriate assays (Ellman <xref ref-type="bibr" rid="CR16">1959</xref>) (Detailed method listed in supporting data). Superoxide dismutase (SOD) (Cat. No, SD 25 21) was measured following the kit instruction obtained from Bio-diagnostic, Egypt (Nishikimi et al. <xref ref-type="bibr" rid="CR48">1972</xref>). Glutathione peroxidase (GPx) (Cat. No. GP 2524) was evaluated using marketable set kit from (Bio-diagnostic, Egypt) (Paglia and Valentine <xref ref-type="bibr" rid="CR51">1967</xref>). Furthermore, the catalase activity (CAT) was estimated using kit obtained from Bio-diagnostic, Egypt (Cat. No. CA 25 17) (Aebi <xref ref-type="bibr" rid="CR2">1984</xref>; Radwan et al. <xref ref-type="bibr" rid="CR55">2021</xref>).</p></sec></sec><sec id="Sec9"><title>Immunoblotting analysis</title><p id="Par11">Protein concentration was determined using a Bradford assay Abcam kit (Cat. No. ab102535), and protein was extracted from hippocampus tissues using a specific protein extraction kit set from Abcam (Cat. No. ab270054). Protein samples (20&#x000a0;&#x000b5;g) were separated on 12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was blocked with skimmed milk and incubated with 1:1000 diluted primary antibodies; A&#x003b2; (Cat. No. 2454) (Verma et al. <xref ref-type="bibr" rid="CR69">2023</xref>) that provided by Cell Signaling, Massachusetts, USA) and IRS-2 (Cat. No. sc-390761, Santa Cruz Biotechnology, Texas, USA) (Chen et al. <xref ref-type="bibr" rid="CR11">2021</xref>) followed by secondary antibodies (HPR-goat anti-rabbit IgG (H&#x00026;L), (ab205718), Abcam, UK). &#x003b2; actin (sc-69879, Sant Cruz) was used as internal control. The specificity of the antibodies was not confirmed in the current study, we based on the supplier company guidelines and appearance single band on the membrane. Protein bands were visualized using chemiluminescence (ECL) and further quantified using ImageJ 1.39P software (National institute of health, USA) (Beverloo et al. <xref ref-type="bibr" rid="CR8">1992</xref>; Radwan et al. <xref ref-type="bibr" rid="CR55">2021</xref>).</p></sec><sec id="Sec10"><title>Histopathological and immunohistochemical investigations</title><p id="Par12">Hippocampus and pancreas tissues were preserved in formaldehyde, processed, and sectioned for histopathological examination using hematoxylin and eosin staining (Tousson et al. <xref ref-type="bibr" rid="CR66">2012</xref>). For immunohistology, Hippocampus sections were deparaffinized, hydrated, and treated with hydrogen peroxide blocking solution before incubation with 1:1000 diluted primary antibodies GFAP (Cat. No. No. Z0334) (G&#x000fc;nther et al. <xref ref-type="bibr" rid="CR24">2021</xref>) and calretinin (Cat. No. No. IR627) (den Braber-Ymker et al. <xref ref-type="bibr" rid="CR14">2017</xref>) which were supplied by Agilent Dako (Santa Clara, CA, United States) then incubated with secondary antibody peroxidase conjugated (EnVision kit, Cat. No. K40023, Dako; Agilent). Finally, about three microscopic fields for each sample were recorded for all different samples (<italic>n</italic>&#x02009;=&#x02009;5) in each experimental group utilizing Olympus microscope (BX41) with digital canon 620 camera (Olympus Corporation). The contrast and resolution were improved using Adobe photoshop package. For quantitative analysis of immunohistology reactions, ImageJ software was utilized to calculate the interaction area related to the total area of the filed (Happerfield et al. <xref ref-type="bibr" rid="CR26">1993</xref>; Guinard-Samuel et al. <xref ref-type="bibr" rid="CR23">2009</xref>; Amin et al. <xref ref-type="bibr" rid="CR4">2013</xref>).</p><sec id="Sec11"><title>Statistical assessment</title><p id="Par13">The sample size (n) in the study was determined based on a level of confidence (95%) and population size (<italic>N</italic>&#x02009;=&#x02009;10) which involved in the study (Supporting information for details). Data analysis was conducted using GraphPad Prism software version 6. One-way ANOVA with Tukey&#x02019;s multiple comparison test was employed to compare measurable variables between study groups. Data are presented as mean&#x02009;&#x000b1;&#x02009;SD, and a significance level of <italic>p</italic>&#x02009;&#x02264;&#x02009;0.05 was considered statistically significant (Altman <xref ref-type="bibr" rid="CR3">2005</xref><bold>)</bold>. Additionally, the normality and homogeneity of samples were employed using D&#x02019;Agostino-Pearson omnibus and Shapiro-Wilk tests in GraphPad prism. The Data which is not normally distributed was analyzed by one-way ANOVA (nonparametric) with Bonferroni-Holm correction using GraphPad prism and presented as median with interquartile range.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Metformin helps improve memory and learning in rats with Alzheimer&#x02019;s disease</title><p id="Par14">As depicted in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, administration of D-gal and AlCl<sub>3</sub> led to significant deficits (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in learning and spatial memory in the AD-induced rats (G4) compared to the control group (G1). Furthermore, when compared to the untreated AD-induced rats (G4), treatment with 200&#x000a0;mg/kg of metformin resulted in improved memory with a notable reduction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in arrival time in the AD-metformin treated group (G5). Notably, no substantial change in arrival time was observed in non-AD groups receiving saline (G2) or metformin (G3) in comparison to the control group (G1). Additionally, there was a clear reduction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in body weight in the AD rat model compared to controls, which was restored following metformin administration. Moreover, the brain weights did not exhibit meaningful reductions in AD rats when compared to the control group (Fig. S1, supporting data).</p><p id="Par15">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Metformin improves the arrival time using the labyrinth in an AD-induced rat model. The results were presented as mean&#x02009;&#x000b1;&#x02009;SD, (<italic>n</italic>&#x02009;=&#x02009;10). where <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. normal group and <sup>####</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. AD-rat model</p></caption><graphic xlink:href="11011_2024_1422_Fig1_HTML" id="d33e465"/></fig>
</p></sec><sec id="Sec14"><title>Metformin assists in lowering hyperglycemia, enhancing insulin sensitivity, and mitigating liver and kidney impairments in AD rats</title><p id="Par16">AD is closely linked to metabolic disorders like diabetes and can affect various bodily processes. So, we measured glucose levels, insulin resistance, and the functioning of the kidneys and liver. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, our serum analysis data revealed a substantial increase (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in HbA1c, glucose levels, insulin, and insulin resistance (HOMA-IR) in the AD model group (G4) in contrast to the control group (G1). Furthermore, post-treatment of AD-induced rats (G5) with a 200&#x000a0;mg/kg dose of metformin exhibited a marked reduction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in the aforementioned biomarkers compared to untreated AD rats (G4). Moreover, AD-induced rats (G4) displayed impaired liver and kidney function along with decreased serum iron and zinc levels, which were subsequently improved after metformin treatment (Table S1, supporting data). Additionally, as summarized in (Table S1, supporting data), the AD rat model demonstrated elevated levels of cholesterol, triacylglycerol, and LDL, accompanied by a notable reduction in HDL.</p><p id="Par17">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Metformin lowers serum HbA1c, glucose, insulin, and HOMA IR in an AD-induced rat model. (A): The level of glycated hemoglobin in treated rats. (B): The glucose level of the rats involved in the study. (C) the level of insulin in all rats. (D) HOMA IR, insulin resistance marker, in all groups. The results were presented as mean&#x02009;&#x000b1;&#x02009;SD, (<italic>n</italic>&#x02009;=&#x02009;10), where <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. normal group and <sup>####</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. AD-rat model</p></caption><graphic xlink:href="11011_2024_1422_Fig2_HTML" id="d33e500"/></fig>
</p></sec><sec id="Sec15"><title>Metformin improves neurochemical transmitters in AD rats</title><p id="Par18">Hippocampal neurotransmitters such as dopamine, acetylcholine, and acetylcholine esterase were measured in the current study as they played a substantial role in AD pathogenesis. The obtained data indicated a pronounced decrease in dopamine (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and acetylcholine (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) levels, along with a real increase (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in acetylcholine esterase activity in AD rats compared to control (G1). Importantly, the levels of these neurotransmitters were ameliorated in AD rats treated with metformin (G5) after a four-week administration of 200&#x000a0;mg/kg metformin, as depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A and B, and <xref rid="Fig3" ref-type="fig">3</xref>C. Additionally, iron (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and zinc (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) levels were extensively raised in the AD rat model (G4) compared to the control group (G1). Importantly, iron and zinc levels were dropped after metformin administration (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in AD-post treated rats (G5) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D and E).</p><p id="Par19">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Metformin boosts neurotransmitters in the hippocampus. (A): Hippocampal dopamine level in treated rats. (B): Hippocampal acetylcholine level in all treated rats. (C): activity of acetylcholine esterase in hippocampus tissues in rats involved in this study. (D): iron level in hippocampus tissue. (E): Hippocampal zinc concentration in treated rats. The results were described as median with interquartile range, (<italic>n</italic>&#x02009;=&#x02009;10), where <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. normal group and <sup>##</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>####</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. AD-rat model</p></caption><graphic xlink:href="11011_2024_1422_Fig3_HTML" id="d33e558"/></fig>
</p></sec><sec id="Sec16"><title>Metformin mitigates oxidative status and enhances the antioxidant system in an AD rat model</title><p id="Par20">The progression of AD is exacerbated by the well-established involvement of oxidative stress. ANOVA analysis of hippocampal oxidative status revealed a substantial increase (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in hippocampal MDA, a marker of oxidative stress, in AD rats (G4) compared to the control group. Treatment with 200&#x000a0;mg/kg of metformin was associated with a large drop (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in hippocampal MDA levels compared to the AD model (G4) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). Additionally, the increased MDA levels in AD rats were accompanied by decreased levels of all antioxidant markers: glutathione (GSH) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), superoxide dismutase (SOD) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), glutathione peroxidase (GPx) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), and catalase (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) compared to the control group (G1). Administration of metformin pointedly enhanced antioxidant markers GSH (<italic>p</italic>&#x02009;=&#x02009;0.0081), SOD (<italic>p</italic>&#x02009;=&#x02009;0.0448), GPx (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), and catalase (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in AD rats (G4) as shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B, C and D, and <xref rid="Fig4" ref-type="fig">4</xref>E, respectively.</p><p id="Par21">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Metformin mitigates oxidative stress and triggers antioxidants in hippocampus. (A): Hippocampal malonaldehyde (MDA) level in treated rats. (B): Hippocampal glutathione (GSH) in all treated rats. (C): The activity of superoxide dismutase (SOD) in hippocampus tissues in rats involved in this study. (D): Glutathione peroxidase activity (GPx) in hippocampus tissues. (E): Hippocampal catalase activity (CAT) in treated rats. The results were presented as median and interquartile range, (<italic>n</italic>&#x02009;=&#x02009;10), where <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001vs normal group and <sup>##</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>####</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. AD-rat model</p></caption><graphic xlink:href="11011_2024_1422_Fig4_HTML" id="d33e629"/></fig>
</p></sec><sec id="Sec17"><title>Metformin lowers hippocampal A&#x003b2; deposition and insulin resistance</title><p id="Par22">The impact of metformin on the formation of A&#x003b2; plaques, a well-known marker of AD, was explored through western blot analysis. Immunoblotting revealed an increase in A&#x003b2; deposition in the AD model (G4), which were reduced following metformin administration in the AD&#x02009;+&#x02009;Metformin group (G5). To assess insulin resistance in the brains of AD rats, insulin receptor substrate 2 (IRS-2) levels were measured, revealing a decrease compared to controls. Importantly, metformin treatment ameliorated this decline in the insulin signaling pathway (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par23">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Influence of metformin on amyloid &#x003b2; aggregation (A&#x003b2;<sub>40/42</sub>) and insulin receptor substrate-2 (IRS-2) in AD- induced rats and after they received 200&#x000a0;mg/kg of metformin</p></caption><graphic xlink:href="11011_2024_1422_Fig5_HTML" id="d33e649"/></fig>
</p></sec><sec id="Sec18"><title>Metformin alleviates histopathological alterations in the AD model</title><p id="Par24">AD is accompanied by structural changes such as neurons deprivation and neurofibrillary tangles. Hence, histological investigation is used as diagnostic machine for AD. Hippocampal sections of control rats (normal and metformin-treated) displayed well-organized and compact pyramidal cells with a normal molecular layer (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A and B). In contrast, the hippocampus of AD-induced rats exhibited pyramidal cell disorganization and vacuolation, along with enlarged neurons and glial cells in the molecular layer (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C). Treatment with metformin led to enhanced pyramidal cell organization, reduced vacuolation, and relatively normal cells in the molecular layer (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D). Additionally, photomicrographs of pancreatic tissue from control rats (normal and metformin-treated) revealed typical rounded Langerhans islets with normal &#x003b2;-cell distribution (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A and B). In the AD rat model, numerous vacuoles and overall distortion of Langerhans islet shape were observed (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C). Metformin treatment restored the normal shape of Langerhans islets and reduced vacuole formation (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>D).</p><p id="Par25">
<fig id="Fig6"><label>Fig. 6</label><caption><p>Hematoxylin and eosin-stained hippocampal sections of all treated rats. (<bold>A</bold>): normal rats. (<bold>B</bold>): rats received 200&#x000a0;mg/kg of metformin. (<bold>C</bold>): AD-induced rats. (<bold>D</bold>): AD-rats treated with 200&#x000a0;mg/kg of metformin for one month</p></caption><graphic xlink:href="11011_2024_1422_Fig6_HTML" id="d33e695"/></fig>
</p><p id="Par26">
<fig id="Fig7"><label>Fig. 7</label><caption><p>Pancreatic sections of all treated rats. (<bold>A</bold>): normal rats. (<bold>B</bold>): rats received 200&#x000a0;mg/kg of metformin. (<bold>C</bold>): AD-induced rats. (<bold>D</bold>): AD-rats treated with 200&#x000a0;mg/kg of metformin for one month</p></caption><graphic xlink:href="11011_2024_1422_Fig7_HTML" id="d33e718"/></fig>
</p></sec><sec id="Sec19"><title>Metformin lessens the immunoreactivity of GFAP and enhances calretinin in AD rats</title><p id="Par27">GFAP and calretinin, modulators of interneuron, were reported to be linked to A&#x003b2; aggregation. Immunostaining of GFAP in the hippocampus of normal and metformin-treated groups displayed minimal reaction and normal spreading (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A and B). AD rats exhibited increased GFAP reaction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) compared to control (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>C), which was attenuated in AD rats treated with metformin (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) compared to AD rats (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>D). Similarly, calretinin showed strong immunoreactivity in normal and metformin-treated groups (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>A and B), decreased in the AD group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), and then increased after metformin treatment (<italic>p</italic>&#x02009;=&#x02009;0.0019) compared to AD rats (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>C and D).</p><p id="Par28">
<fig id="Fig8"><label>Fig. 8</label><caption><p>Hippocampal GFAP immunoreactivity. (<bold>A</bold>): normal rats. (<bold>B</bold>): normal rats received metformin. (<bold>C</bold>): AD-rat model. (<bold>D</bold>): AD-rats treated with 200&#x000a0;mg/kg of metformin. (<bold>E</bold>): representative histography of %area of GFAP expression analyzed utilizing ImageJ (<italic>n</italic>&#x02009;=&#x02009;5). where <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. normal and <sup>####</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. AD model</p></caption><graphic xlink:href="11011_2024_1422_Fig8_HTML" id="d33e788"/></fig>
</p><p id="Par29">
<fig id="Fig9"><label>Fig. 9</label><caption><p>Hippocampal calretinin immunoreactivity. (<bold>A</bold>): normal rats. (<bold>B</bold>): normal rats received metformin. (<bold>C</bold>): AD-rat model. (<bold>D</bold>): AD-rats treated with 200&#x000a0;mg/kg of metformin. (<bold>E</bold>): representative histography of %area of calretinin immunoreactivity analyzed utilizing ImageJ (<italic>n</italic>&#x02009;=&#x02009;5). where <sup>****</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. normal and <sup>##</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>####</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 vs. AD model</p></caption><graphic xlink:href="11011_2024_1422_Fig9_HTML" id="d33e830"/></fig>
</p></sec></sec><sec id="Sec20" sec-type="discussion"><title>Discussion</title><p id="Par30">Alzheimer&#x02019;s disease (AD) is a progressively growing concern, with its inextricable link to aging presenting a formidable challenge (Tzioras et al. <xref ref-type="bibr" rid="CR67">2023</xref>). Consequently, addressing AD effectively requires a thorough understanding of its mechanistic underpinnings and their connections to related disorders, to identify viable therapeutic avenues. This study delved into the potential role of metformin in treating AD and sought to establish a connection between AD pathogenesis and insulin resistance within the brain. According to the outcomes of the existing study, metformin, a medication commonly prescribed for diabetes, has the potential to enhance cognitive function, alleviate stress, improve neurotransmitter activity, and enhance insulin pathways within the brain. The possible outcome of this could result in beneficial effects for alleviating symptoms of Alzheimer&#x02019;s disease.</p><p id="Par31">Additionally, the study&#x02019;s findings shed light on the multifaceted impact of AD induction through D-gal and AlCl<sub>3</sub>, which not only manifested in cognitive decline but also encompassed physical alterations such as weight loss in the rats. A discernible trend towards memory impairment was observed, alongside elevated glucose levels and diminished brain weight. It was discerned that AD induction exerted a detrimental influence on the frontal memory region, potentially causing neuronal damage and concomitant reductions in brain glucose levels and energy metabolism. These observations resonated with the work of Nitsch et al., who demonstrated the interplay between glucose, energy levels, and cognitive faculties (Nitsch and Hoyer <xref ref-type="bibr" rid="CR49">1991</xref>). Moreover, prior studies have established correlations between AD induction, fluctuations in glucose levels, and cognitive dysfunction (Amin et al. <xref ref-type="bibr" rid="CR4">2013</xref>; Mostafa et al. <xref ref-type="bibr" rid="CR44">2016</xref>; Tanokashira et al. <xref ref-type="bibr" rid="CR64">2018</xref>).</p><p id="Par32">Notably, the study illuminated that AD&#x02019;s impact extended beyond cognitive impairment, impacting crucial organs and systems, including liver and kidney function alterations driven by lipid and ion imbalances. The observed increase in liver function was in line with previous research associating liver function, particularly non-alcoholic liver disease, with heightened dementia risk (Solfrizzi et al. <xref ref-type="bibr" rid="CR61">2020</xref>; Shang et al. <xref ref-type="bibr" rid="CR59">2022</xref>). Similarly, a study in chronic schizophrenia highlighted increased C-reactive protein, an indicator of liver response to endotoxins (Liu et al. <xref ref-type="bibr" rid="CR38">2022</xref>). A former study also corroborated prior evidence linking cognitive impairment with end-stage renal disease and severity-scaled cognitive decline in chronic kidney disease (Murray et al. <xref ref-type="bibr" rid="CR45">2006</xref>).</p><p id="Par33">Crucially, the study identified elevated glucose, HbA1C, and HOMA-IR levels as markers of insulin resistance. This phenomenon has been linked to diminished glucose metabolism in the brain and increased A&#x003b2; deposition. Impaired insulin signaling is a hallmark of AD, prompting some to label it &#x0201c;type 3 diabetes&#x0201d; due to its ramifications on memory and cognitive function (Wakabayashi et al. <xref ref-type="bibr" rid="CR70">2019</xref>). Encouragingly, metformin administration effectively ameliorated blood sugar control, HOMA-IR, and HbA1c in AD rats. These findings aligned with existing literature (Derosa et al. <xref ref-type="bibr" rid="CR15">2017</xref>; Liu et al. <xref ref-type="bibr" rid="CR38">2022</xref>).</p><p id="Par34">Furthermore, AD&#x02019;s impact on the insulin signaling pathway manifested in heightened hepatic glucose and lipid production, culminating in lipotoxicity (Kelley et al. <xref ref-type="bibr" rid="CR29">2003</xref>; Bugianesi et al. <xref ref-type="bibr" rid="CR9">2005</xref>). Noteworthy alterations in free fatty acid levels, apoB decomposition, hypertriglyceridemia, and HDL levels also occurred (Ormazabal et al. <xref ref-type="bibr" rid="CR50">2018</xref>) Metformin treatment effectively mitigated total cholesterol, LDL, and triglyceride levels (Gillani et al. <xref ref-type="bibr" rid="CR19">2021</xref>). The study underscored the pivotal roles of oxidative stress and neuroinflammation in AD pathogenesis (Li et al. <xref ref-type="bibr" rid="CR35">2023</xref>). Previous experiments have attested to oxidative stress&#x02019;s contribution to AD onset through A&#x003b2;-mediated mechanisms, inducing mitochondrial dysfunction, glucose metabolism disruption, synaptic plasticity diminishing, distorted signal transduction, neuronal injury, and progressive neurodegeneration (Butterfield and Boyd-Kimball <xref ref-type="bibr" rid="CR10">2019</xref>; Hampel et al. <xref ref-type="bibr" rid="CR25">2021</xref>). Consistent with these findings, chemically induced AD displayed elevated inflammatory indicators and oxidative stress, alongside weakened antioxidant systems (Kazmi et al. <xref ref-type="bibr" rid="CR28">2023</xref>). Metformin effectively reduced hippocampal oxidative stress and enhanced antioxidant defenses, aligning with similar research demonstrating metformin&#x02019;s capacity to lower malondialdehyde levels and elevate total antioxidant capacity (Gorgich et al. <xref ref-type="bibr" rid="CR20">2021</xref>).</p><p id="Par35">The elevation of oxidative stress paralleled heightened hippocampal iron and zinc levels, potentially contributing to free radical generation via Fenton reactions, a phenomenon implicated in neurodegenerative (Gozzelino and Arosio <xref ref-type="bibr" rid="CR21">2016</xref>). These findings corroborated earlier studies indicating elevated ion levels, including iron, zinc, and copper, in sporadic AD (Lovell et al. <xref ref-type="bibr" rid="CR39">1998</xref>). Notably, metformin&#x02019;s ameliorative effects on these anomalies resonated with prior reports (Mascitelli and Pezzetta <xref ref-type="bibr" rid="CR41">2008</xref>; Mustafa et al. <xref ref-type="bibr" rid="CR46">2022</xref>).</p><p id="Par36">Neurotransmitter assessment illuminated notable declines in dopamine and acetylcholine levels, coupled with heightened acetylcholine esterase activity, a pattern ameliorated by metformin treatment. These findings concurred with studies showcasing metformin&#x02019;s potential to rectify synaptic deficits, enhance memory, and improve cognition in AD animal models (Pilipenko et al. <xref ref-type="bibr" rid="CR54">2020</xref>; Saffari et al. <xref ref-type="bibr" rid="CR58">2020</xref>; Thinnes et al. <xref ref-type="bibr" rid="CR65">2021</xref>).</p><p id="Par37">Consequently, the study demonstrated that metformin effectively reduced A&#x003b2; levels. These findings mirrored previous investigations wherein metformin attenuated hippocampal A&#x003b2;1&#x02013;42 levels (Li et al. <xref ref-type="bibr" rid="CR34">2012</xref>). Correspondingly, metformin&#x02019;s potential to ameliorate microglial autophagy impairment and mitigate A&#x003b2; load and NP tau pathology was consonant with Chen et al.&#x02018;s findings (Chen et al. <xref ref-type="bibr" rid="CR11">2021</xref>). The study further scrutinized IRS-2, a key component of insulin signaling in the brain. Notably, sporadic AD displayed diminished IRS-2 levels, a deficit ameliorated by metformin treatment. These results harmonized with studies demonstrating metformin-induced IRS-2 upregulation (Rice et al. <xref ref-type="bibr" rid="CR56">2011</xref>).</p><p id="Par38">Early pathology and immunohistopathology of hippocampal were investigated in the current study. Histopathological examination unveiled neuronal damage and degeneration, accompanied by robust astrogliosis (GFAP immunoreactivity) and attenuated calretinin staining in AD rats. Encouragingly, metformin mitigated these adverse effects, in line with prior research highlighting metformin&#x02019;s potential to ameliorate hippocampal microgliosis (Pilipenko et al. <xref ref-type="bibr" rid="CR54">2020</xref>). The decrease in GFAP expression resonated with Miguel-Hidalgo&#x02019;s findings, indicating the neuroprotective power of memantine on &#x003b2;-amyloid-induced rat models, and concluded that memantine-treated animals had noteworthy falls in GFAP immunostaining (Miguel-Hidalgo et al. <xref ref-type="bibr" rid="CR43">2002</xref>).</p><p id="Par39">In conclusion, this study revealed the intertwining nature of AD and insulin signaling, emphasizing their interconnectedness rather than treating them as isolated phenomena. Importantly, metformin emerges as an encouraging therapeutic agent for addressing AD, shedding light on its potential to mitigate cognitive decline and tackle the intricate mechanisms.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Electronic Supplementary Material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11011_2024_1422_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1 (DOCX 631 KB)</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, Supervision, writing-review&#x00026;editing (H. A. A, E. T and T. M. M). Formal analysis, Methodology (H. A. A, E.T and Y. E). Writing original draft (H. A. A and Y. E).</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data that support the current study are available in the manuscript and supporting data file.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par40">The rats involved in this study was handled and maintained according to research animals&#x02019; guidelines followed by Faculty of Science, Tanta University, Egypt that follow AARIVE guidelines (Ethical approval No. IACUC-SCI-TU-0259), consent to participate.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par41">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par42">The authors declare that there is no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Abosharaf</surname><given-names>HA</given-names></name><name><surname>Elsonbaty</surname><given-names>Y</given-names></name><name><surname>Tousson</surname><given-names>E</given-names></name><name><surname>Mohamed</surname><given-names>TM</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease-related brain insulin resistance and the prospective therapeutic impact of metformin</article-title><source>J Neuroendocrinol</source><year>2024</year><volume>36</volume><fpage>e13356</fpage><pub-id pub-id-type="doi">10.1111/jne.13356</pub-id><pub-id pub-id-type="pmid">37985011</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Abosharaf HA, Elsonbaty Y, Tousson E, Mohamed TM (2024) Alzheimer&#x02019;s disease-related brain insulin resistance and the prospective therapeutic impact of metformin. J Neuroendocrinol 36:e13356. 10.1111/jne.13356<pub-id pub-id-type="pmid">37985011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Aebi</surname><given-names>H</given-names></name></person-group><article-title>[13] Catalase in vitro</article-title><source>Methods Enzymol Elsevier</source><year>1984</year><volume>105</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(84)05016-3</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Aebi H (1984) [13] catalase in vitro. Methods Enzymol Elsevier 105:121&#x02013;126</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="book"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>G</given-names></name></person-group><source>Comparing groups: three or more independent groups of observations in practical statistics for medical research</source><year>2005</year><publisher-name>Chapman Hall</publisher-name></element-citation><mixed-citation id="mc-CR3" publication-type="book">Altman G (2005) Comparing groups: three or more independent groups of observations in practical statistics for medical research. Chapman Hall</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>SN</given-names></name><name><surname>Younan</surname><given-names>SM</given-names></name><name><surname>Youssef</surname><given-names>MF</given-names></name><name><surname>Rashed</surname><given-names>LA</given-names></name><name><surname>Mohamady</surname><given-names>I</given-names></name></person-group><article-title>A histological and functional study on hippocampal formation of normal and diabetic rats</article-title><source>F1000Res</source><year>2013</year><volume>2</volume><fpage>151</fpage><pub-id pub-id-type="doi">10.12688/f1000research.2-151.v1</pub-id><pub-id pub-id-type="pmid">24555069</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Amin SN, Younan SM, Youssef MF, Rashed LA, Mohamady I (2013) A histological and functional study on hippocampal formation of normal and diabetic rats. F1000Res 2:151. 10.12688/f1000research.2-151.v1<pub-id pub-id-type="pmid">24555069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Apter</surname><given-names>JT</given-names></name><name><surname>Shastri</surname><given-names>K</given-names></name><name><surname>Pizano</surname><given-names>K</given-names></name></person-group><article-title>Update on disease-modifying/preventive therapies in Alzheimer&#x02019;s disease</article-title><source>Curr Geriatr Rep</source><year>2015</year><volume>4</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1007/s13670-015-0141-x</pub-id><pub-id pub-id-type="pmid">26543800</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Apter JT, Shastri K, Pizano K (2015) Update on disease-modifying/preventive therapies in Alzheimer&#x02019;s disease. Curr Geriatr Rep 4:312&#x02013;317<pub-id pub-id-type="pmid">26543800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Beeri</surname><given-names>M</given-names></name><name><surname>Schmeidler</surname><given-names>J</given-names></name><name><surname>Silverman</surname><given-names>J</given-names></name><name><surname>Gandy</surname><given-names>S</given-names></name><name><surname>Wysocki</surname><given-names>M</given-names></name><name><surname>Hannigan</surname><given-names>C</given-names></name><name><surname>Purohit</surname><given-names>D</given-names></name><name><surname>Lesser</surname><given-names>G</given-names></name><name><surname>Grossman</surname><given-names>H</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name></person-group><article-title>Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>750</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000324925.95210.6d</pub-id><pub-id pub-id-type="pmid">18765651</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Beeri M, Schmeidler J, Silverman J, Gandy S, Wysocki M, Hannigan C, Purohit D, Lesser G, Grossman H, Haroutunian V (2008) Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71:750&#x02013;757. 10.1212/01.wnl.0000324925.95210.6d<pub-id pub-id-type="pmid">18765651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><mixed-citation publication-type="other">Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, De Ferranti SD, Floyd J, Fornage M, Gillespie C (2017) Heart disease and stroke statistics&#x02014;2017 update: a report from the American Heart Association. Circulation. 135: e146-e603</mixed-citation></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Beverloo</surname><given-names>HB</given-names></name><name><surname>van Schadewijk</surname><given-names>A</given-names></name><name><surname>Zijlmans</surname><given-names>HJ</given-names></name><name><surname>Tanke</surname><given-names>HJ</given-names></name></person-group><article-title>Immunochemical detection of proteins and nucleic acids on filters using small luminescent inorganic crystals as markers</article-title><source>Anal Biochem</source><year>1992</year><volume>203</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(92)90320-7</pub-id><pub-id pub-id-type="pmid">1416029</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Beverloo HB, van Schadewijk A, Zijlmans HJ, Tanke HJ (1992) Immunochemical detection of proteins and nucleic acids on filters using small luminescent inorganic crystals as markers. Anal Biochem 203:326&#x02013;334. 10.1016/0003-2697(92)90320-7<pub-id pub-id-type="pmid">1416029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name><name><surname>Marchesini</surname><given-names>G</given-names></name></person-group><article-title>Insulin resistance: a metabolic pathway to chronic liver disease</article-title><source>Hepatology</source><year>2005</year><volume>42</volume><fpage>987</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1002/hep.20920</pub-id><pub-id pub-id-type="pmid">16250043</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bugianesi E, McCullough AJ, Marchesini G (2005) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42:987&#x02013;1000. 10.1002/hep.20920<pub-id pub-id-type="pmid">16250043</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Butterfield</surname><given-names>DA</given-names></name><name><surname>Boyd-Kimball</surname><given-names>D</given-names></name></person-group><article-title>Redox proteomics and amyloid &#x003b2;&#x02010;peptide: insights into Alzheimer disease</article-title><source>J Neurochem</source><year>2019</year><volume>151</volume><fpage>459</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1111/jnc.14589</pub-id><pub-id pub-id-type="pmid">30216447</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Butterfield DA, Boyd-Kimball D (2019) Redox proteomics and amyloid &#x003b2;&#x02010;peptide: insights into Alzheimer disease. J Neurochem 151:459&#x02013;487<pub-id pub-id-type="pmid">30216447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>Metformin attenuates plaque-associated tau pathology and reduces amyloid-&#x003b2; burden in APP/PS1 mice</article-title><source>Alzheimers Res Ther</source><year>2021</year><volume>13</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s13195-020-00761-9</pub-id><pub-id pub-id-type="pmid">33563332</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen Y, Zhao S, Fan Z, Li Z, Zhu Y, Shen T, Li K, Yan Y, Tian J, Liu Z, Zhang B (2021) Metformin attenuates plaque-associated tau pathology and reduces amyloid-&#x003b2; burden in APP/PS1 mice. Alzheimers Res Ther 13:40. 10.1186/s13195-020-00761-9<pub-id pub-id-type="pmid">33563332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>C</given-names></name><name><surname>Cafferty</surname><given-names>F</given-names></name><name><surname>Vale</surname><given-names>C</given-names></name><name><surname>Langley</surname><given-names>R</given-names></name></person-group><article-title>Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><fpage>2184</fpage><lpage>2195</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw410</pub-id><pub-id pub-id-type="pmid">27681864</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Coyle C, Cafferty F, Vale C, Langley R (2016) Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 27:2184&#x02013;2195<pub-id pub-id-type="pmid">27681864</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>RM</given-names></name></person-group><article-title>Housing, husbandry and handling of rodents for behavioral experiments</article-title><source>Nat Protoc</source><year>2006</year><volume>1</volume><fpage>936</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.120</pub-id><pub-id pub-id-type="pmid">17406327</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Deacon RM (2006) Housing, husbandry and handling of rodents for behavioral experiments. Nat Protoc 1:936&#x02013;946. 10.1038/nprot.2006.120<pub-id pub-id-type="pmid">17406327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>den Braber-Ymker</surname><given-names>M</given-names></name><name><surname>Lammens</surname><given-names>M</given-names></name><name><surname>van Putten</surname><given-names>MJAM</given-names></name><name><surname>Nagtegaal</surname><given-names>ID</given-names></name></person-group><article-title>The enteric nervous system and the musculature of the colon are altered in patients with spina bifida and spinal cord injury</article-title><source>Virchows Arch</source><year>2017</year><volume>470</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s00428-016-2060-4</pub-id><pub-id pub-id-type="pmid">28062917</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">den Braber-Ymker M, Lammens M, van Putten MJAM, Nagtegaal ID (2017) The enteric nervous system and the musculature of the colon are altered in patients with spina bifida and spinal cord injury. Virchows Arch 470:175&#x02013;184. 10.1007/s00428-016-2060-4<pub-id pub-id-type="pmid">28062917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="book"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>A</given-names></name><name><surname>Romano</surname><given-names>D</given-names></name><name><surname>Maffioli</surname><given-names>P</given-names></name></person-group><source>Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes</source><year>2017</year><publisher-name>Drug Design, Development and Therapy</publisher-name><fpage>1481</fpage><lpage>1488</lpage></element-citation><mixed-citation id="mc-CR15" publication-type="book">Derosa G, D&#x02019;Angelo A, Romano D, Maffioli P (2017) Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Design, Development and Therapy, pp 1481&#x02013;1488</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Ellman</surname><given-names>GL</given-names></name></person-group><article-title>Tissue sulfhydryl groups</article-title><source>Arch Biochem Biophys</source><year>1959</year><volume>82</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/0003-9861(59)90090-6</pub-id><pub-id pub-id-type="pmid">13650640</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70&#x02013;77. 10.1016/0003-9861(59)90090-6<pub-id pub-id-type="pmid">13650640</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrannini</surname><given-names>E</given-names></name></person-group><article-title>The target of Metformin in Type 2 diabetes</article-title><source>New Engl J Med</source><year>2014</year><volume>371</volume><fpage>1547</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1056/NEJMcibr1409796</pub-id><pub-id pub-id-type="pmid">25317875</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ferrannini E (2014) The target of Metformin in Type 2 diabetes. New Engl J Med 371:1547&#x02013;1548. 10.1056/NEJMcibr1409796<pub-id pub-id-type="pmid">25317875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gasmi</surname><given-names>S</given-names></name></person-group><article-title>Classic Labyrinth Test for Neurobehavioral evaluation in Wistar rats</article-title><source>Bio Protoc</source><year>2018</year><volume>8</volume><fpage>e3007</fpage><pub-id pub-id-type="doi">10.21769/BioProtoc.3007</pub-id><pub-id pub-id-type="pmid">34395798</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gasmi S (2018) Classic Labyrinth Test for Neurobehavioral evaluation in Wistar rats. Bio Protoc 8:e3007. 10.21769/BioProtoc.3007<pub-id pub-id-type="pmid">34395798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Gillani</surname><given-names>SW</given-names></name><name><surname>Ghayedi</surname><given-names>N</given-names></name><name><surname>Roosta</surname><given-names>P</given-names></name><name><surname>Seddigh</surname><given-names>P</given-names></name><name><surname>Nasiri</surname><given-names>O</given-names></name></person-group><article-title>Effect of metformin on lipid profiles of type 2 diabetes Mellitus: a Meta-analysis of Randomized controlled trials</article-title><source>J Pharm Bioallied Sci</source><year>2021</year><volume>13</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.4103/jpbs.JPBS_370_20</pub-id><pub-id pub-id-type="pmid">34084051</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gillani SW, Ghayedi N, Roosta P, Seddigh P, Nasiri O (2021) Effect of metformin on lipid profiles of type 2 diabetes Mellitus: a Meta-analysis of Randomized controlled trials. J Pharm Bioallied Sci 13:76&#x02013;82. 10.4103/jpbs.JPBS_370_20<pub-id pub-id-type="pmid">34084051</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorgich</surname><given-names>EAC</given-names></name><name><surname>Parsaie</surname><given-names>H</given-names></name><name><surname>Yarmand</surname><given-names>S</given-names></name><name><surname>Baharvand</surname><given-names>F</given-names></name><name><surname>Sarbishegi</surname><given-names>M</given-names></name></person-group><article-title>Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats</article-title><source>Behav Brain Res</source><year>2021</year><volume>410</volume><fpage>113343</fpage><pub-id pub-id-type="doi">10.1016/j.bbr.2021.113343</pub-id><pub-id pub-id-type="pmid">33965434</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Gorgich EAC, Parsaie H, Yarmand S, Baharvand F, Sarbishegi M (2021) Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats. Behav Brain Res 410:113343. 10.1016/j.bbr.2021.113343<pub-id pub-id-type="pmid">33965434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Gozzelino</surname><given-names>R</given-names></name><name><surname>Arosio</surname><given-names>P</given-names></name></person-group><article-title>Iron Homeostasis in Health and Disease</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.3390/ijms17010130</pub-id><pub-id pub-id-type="pmid">26805813</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gozzelino R, Arosio P (2016) Iron Homeostasis in Health and Disease. Int J Mol Sci 17:130. 10.3390/ijms17010130<pub-id pub-id-type="pmid">26805813</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Grzybowska</surname><given-names>M</given-names></name><name><surname>Bober</surname><given-names>J</given-names></name><name><surname>Olszewska</surname><given-names>M</given-names></name></person-group><article-title>Metformin&#x02013;mechanisms of action and use for the treatment of type 2 diabetes mellitus</article-title><source>Adv Hygiene Experimental Med</source><year>2011</year><volume>65</volume><fpage>277</fpage><lpage>285</lpage></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Grzybowska M, Bober J, Olszewska M (2011) Metformin&#x02013;mechanisms of action and use for the treatment of type 2 diabetes mellitus. Adv Hygiene Experimental Med 65:277&#x02013;285</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Guinard-Samuel</surname><given-names>V</given-names></name><name><surname>Bonnard</surname><given-names>A</given-names></name><name><surname>De Lagausie</surname><given-names>P</given-names></name><name><surname>Philippe-Chomette</surname><given-names>P</given-names></name><name><surname>Alberti</surname><given-names>C</given-names></name><name><surname>El Ghoneimi</surname><given-names>A</given-names></name><name><surname>Peuchmaur</surname><given-names>M</given-names></name><name><surname>Berrebi-Binczak</surname><given-names>D</given-names></name></person-group><article-title>Calretinin immunohistochemistry: a simple and efficient tool to diagnose Hirschsprung disease</article-title><source>Mod Pathol</source><year>2009</year><volume>22</volume><fpage>1379</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2009.110</pub-id><pub-id pub-id-type="pmid">19648883</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Guinard-Samuel V, Bonnard A, De Lagausie P, Philippe-Chomette P, Alberti C, El Ghoneimi A, Peuchmaur M, Berrebi-Binczak D (2009) Calretinin immunohistochemistry: a simple and efficient tool to diagnose Hirschsprung disease. Mod Pathol 22:1379&#x02013;1384. 10.1038/modpathol.2009.110<pub-id pub-id-type="pmid">19648883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;nther</surname><given-names>HS</given-names></name><name><surname>Henne</surname><given-names>S</given-names></name><name><surname>Oehlmann</surname><given-names>J</given-names></name><name><surname>Urban</surname><given-names>J</given-names></name><name><surname>Pleizier</surname><given-names>D</given-names></name><name><surname>Renevier</surname><given-names>N</given-names></name><name><surname>Lohr</surname><given-names>C</given-names></name><name><surname>W&#x000fc;lfing</surname><given-names>C</given-names></name></person-group><article-title>GFAP and desmin expression in lymphatic tissues leads to difficulties in distinguishing between glial and stromal cells</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>13322</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-92364-z</pub-id><pub-id pub-id-type="pmid">34172765</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">G&#x000fc;nther HS, Henne S, Oehlmann J, Urban J, Pleizier D, Renevier N, Lohr C, W&#x000fc;lfing C (2021) GFAP and desmin expression in lymphatic tissues leads to difficulties in distinguishing between glial and stromal cells. Sci Rep 11:13322. 10.1038/s41598-021-92364-z<pub-id pub-id-type="pmid">34172765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name><name><surname>Aisen</surname><given-names>P</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name></person-group><article-title>The amyloid-&#x003b2; pathway in Alzheimer&#x02019;s disease</article-title><source>Mol Psychiatry</source><year>2021</year><volume>26</volume><fpage>5481</fpage><lpage>5503</lpage><pub-id pub-id-type="doi">10.1038/s41380-021-01249-0</pub-id><pub-id pub-id-type="pmid">34456336</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T (2021) The amyloid-&#x003b2; pathway in Alzheimer&#x02019;s disease. Mol Psychiatry 26:5481&#x02013;5503<pub-id pub-id-type="pmid">34456336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Happerfield</surname><given-names>L</given-names></name><name><surname>Bobrow</surname><given-names>L</given-names></name><name><surname>Bains</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>K</given-names></name></person-group><article-title>Peroxidase labelling immunocytochemistry: a comparison of eleven commercially-available avidin-biotin systems</article-title><source>Br J Biomed Sci</source><year>1993</year><volume>50</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">8032290</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Happerfield L, Bobrow L, Bains R, Miller K (1993) Peroxidase labelling immunocytochemistry: a comparison of eleven commercially-available avidin-biotin systems. Br J Biomed Sci 50:21&#x02013;26<pub-id pub-id-type="pmid">8032290</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Amariglio</surname><given-names>RE</given-names></name><name><surname>Van Boxtel</surname><given-names>M</given-names></name><name><surname>Breteler</surname><given-names>M</given-names></name><name><surname>Ceccaldi</surname><given-names>M</given-names></name><name><surname>Ch&#x000e9;telat</surname><given-names>G</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>KA</given-names></name><name><surname>Van Der Flier</surname><given-names>WM</given-names></name></person-group><article-title>A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2014</year><volume>10</volume><fpage>844</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.01.001</pub-id><pub-id pub-id-type="pmid">24798886</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Jessen F, Amariglio RE, Van Boxtel M, Breteler M, Ceccaldi M, Ch&#x000e9;telat G, Dubois B, Dufouil C, Ellis KA, Van Der Flier WM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#x02019;s disease. Alzheimers Dement 10:844&#x02013;852<pub-id pub-id-type="pmid">24798886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kazmi</surname><given-names>I</given-names></name><name><surname>Al-Abbasi</surname><given-names>FA</given-names></name><name><surname>Afzal</surname><given-names>M</given-names></name><name><surname>Shahid Nadeem</surname><given-names>M</given-names></name><name><surname>Altayb</surname><given-names>HN</given-names></name></person-group><article-title>Sterubin protects against chemically-induced Alzheimer&#x02019;s disease by reducing biomarkers of inflammation- IL-6/ IL-&#x003b2;/ TNF-&#x003b1; and oxidative stress- SOD/MDA in rats</article-title><source>Saudi J Biol Sci</source><year>2023</year><volume>30</volume><fpage>103560</fpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2023.103560</pub-id><pub-id pub-id-type="pmid">36712184</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kazmi I, Al-Abbasi FA, Afzal M, Shahid Nadeem M, Altayb HN (2023) Sterubin protects against chemically-induced Alzheimer&#x02019;s disease by reducing biomarkers of inflammation- IL-6/ IL-&#x003b2;/ TNF-&#x003b1; and oxidative stress- SOD/MDA in rats. Saudi J Biol Sci 30:103560. 10.1016/j.sjbs.2023.103560<pub-id pub-id-type="pmid">36712184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>DE</given-names></name><name><surname>McKolanis</surname><given-names>TM</given-names></name><name><surname>Hegazi</surname><given-names>RA</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Kalhan</surname><given-names>SC</given-names></name></person-group><article-title>Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance</article-title><source>Am J Physiol Endocrinol</source><year>2003</year><volume>285</volume><fpage>E906</fpage><lpage>E916</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00117.2003</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC (2003) Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol 285:E906&#x02013;E916. 10.1152/ajpendo.00117.2003</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>W</given-names></name><name><surname>Cuthill</surname><given-names>I</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>D</given-names></name></person-group><article-title>Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research</article-title><source>PLoS Biol</source><year>2010</year><volume>8</volume><issue>6</issue><fpage>e1000412</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000412</pub-id><pub-id pub-id-type="pmid">20613859</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D (2010) Improving Bioscience Research Reporting: the ARRIVE guidelines for Reporting Animal Research. PLoS Biol 8(6):e1000412<pub-id pub-id-type="pmid">20613859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Amieva</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Ch&#x000e9;telat</surname><given-names>G</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Nixon</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>DT</given-names></name></person-group><article-title>Alzheimer disease</article-title><source>Nat Reviews Disease Primers</source><year>2021</year><volume>7</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmid">33986301</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Knopman DS, Amieva H, Petersen RC, Ch&#x000e9;telat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT (2021) Alzheimer disease. Nat Reviews Disease Primers 7:33. 10.1038/s41572-021-00269-y<pub-id pub-id-type="pmid">33986301</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Chakrabarti</surname><given-names>A</given-names></name><name><surname>Sarma</surname><given-names>P</given-names></name><name><surname>Modi</surname><given-names>M</given-names></name><name><surname>Banerjee</surname><given-names>D</given-names></name><name><surname>Radotra</surname><given-names>BD</given-names></name><name><surname>Bhatia</surname><given-names>A</given-names></name><name><surname>Medhi</surname><given-names>B</given-names></name></person-group><article-title>Novel therapeutic mechanism of action of metformin and its nanoformulation in Alzheimer&#x02019;s disease and role of AKT/ERK/GSK pathway</article-title><source>Eur J Pharm Sci</source><year>2023</year><volume>181</volume><fpage>106348</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2022.106348</pub-id><pub-id pub-id-type="pmid">36496166</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kumar H, Chakrabarti A, Sarma P, Modi M, Banerjee D, Radotra BD, Bhatia A, Medhi B (2023) Novel therapeutic mechanism of action of metformin and its nanoformulation in Alzheimer&#x02019;s disease and role of AKT/ERK/GSK pathway. Eur J Pharm Sci 181:106348. 10.1016/j.ejps.2022.106348<pub-id pub-id-type="pmid">36496166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Lambova</surname><given-names>SN</given-names></name></person-group><article-title>Pleiotropic effects of Metformin in Osteoarthritis</article-title><source>Life</source><year>2023</year><volume>13</volume><fpage>437</fpage><pub-id pub-id-type="doi">10.3390/life13020437</pub-id><pub-id pub-id-type="pmid">36836794</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lambova SN (2023) Pleiotropic effects of Metformin in Osteoarthritis. Life 13:437<pub-id pub-id-type="pmid">36836794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Sheng</surname><given-names>W</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name></person-group><article-title>Metformin attenuates Alzheimer&#x02019;s disease-like neuropathology in obese, leptin-resistant mice</article-title><source>Pharmacol Biochem Behav</source><year>2012</year><volume>101</volume><fpage>564</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2012.03.002</pub-id><pub-id pub-id-type="pmid">22425595</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Li J, Deng J, Sheng W, Zuo Z (2012) Metformin attenuates Alzheimer&#x02019;s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101:564&#x02013;574. 10.1016/j.pbb.2012.03.002<pub-id pub-id-type="pmid">22425595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Risacher</surname><given-names>SL</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name></person-group><article-title>Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort</article-title><source>Neurology</source><year>2016</year><volume>87</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000002950</pub-id><pub-id pub-id-type="pmid">27385744</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Li W, Risacher SL, Huang E, Saykin AJ (2016) Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort. Neurology 87:595&#x02013;600. 10.1212/wnl.0000000000002950<pub-id pub-id-type="pmid">27385744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>Identification and validation of oxidative stress and immune-related hub genes in Alzheimer&#x02019;s disease through bioinformatics analysis</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><fpage>657</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-27977-7</pub-id><pub-id pub-id-type="pmid">36635346</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Li S, Xiao J, Huang C, Sun J (2023) Identification and validation of oxidative stress and immune-related hub genes in Alzheimer&#x02019;s disease through bioinformatics analysis. Sci Rep 13:657. 10.1038/s41598-023-27977-7<pub-id pub-id-type="pmid">36635346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><mixed-citation publication-type="other">Liu Z, Zhang Y, Wang J, Xia L, Yang Y, Sun L, Zhang D, Li W, Yao X, Yang R, Liu Y, Liu H (2022) Association of higher plasma leptin levels with HOMA-IR index, high sensitivity C-reactive protein and glycolipid metabolism in patients with chronic schizophrenia: a multi-center cross-sectional study. Front Psychiatry 13. 10.3389/fpsyt.2022.992988</mixed-citation></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Tiselius</surname><given-names>H-G</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Xing</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name></person-group><article-title>Metformin suppresses calcium oxalate crystal-induced kidney injury by promoting Sirt1 and M2 macrophage-mediated anti-inflammatory activation</article-title><source>Signal Transduct Target Therapy</source><year>2023</year><volume>8</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01232-3</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Liu H, Duan C, Yang X, Liu J, Deng Y, Tiselius H-G, Ye Z, Wang T, Xing J, Xu H (2023) Metformin suppresses calcium oxalate crystal-induced kidney injury by promoting Sirt1 and M2 macrophage-mediated anti-inflammatory activation. Signal Transduct Target Therapy 8:38. 10.1038/s41392-022-01232-3</mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Lovell</surname><given-names>MA</given-names></name><name><surname>Robertson</surname><given-names>JD</given-names></name><name><surname>Teesdale</surname><given-names>WJ</given-names></name><name><surname>Campbell</surname><given-names>JL</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name></person-group><article-title>Copper, iron and zinc in Alzheimer&#x02019;s disease senile plaques</article-title><source>J Neurol Sci</source><year>1998</year><volume>158</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/s0022-510x(98)00092-6</pub-id><pub-id pub-id-type="pmid">9667777</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer&#x02019;s disease senile plaques. J Neurol Sci 158:47&#x02013;52. 10.1016/s0022-510x(98)00092-6<pub-id pub-id-type="pmid">9667777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Mallikarjuna</surname><given-names>N</given-names></name><name><surname>Praveen</surname><given-names>K</given-names></name><name><surname>Yellamma</surname><given-names>K</given-names></name></person-group><article-title>Role of Lactobacillus plantarum MTCC1325 in membrane-bound transport ATPases system in Alzheimer&#x02019;s disease-induced rat brain</article-title><source>BioImpacts: BI</source><year>2016</year><volume>6</volume><fpage>203</fpage><pub-id pub-id-type="doi">10.15171/bi.2016.27</pub-id><pub-id pub-id-type="pmid">28265536</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mallikarjuna N, Praveen K, Yellamma K (2016) Role of Lactobacillus plantarum MTCC1325 in membrane-bound transport ATPases system in Alzheimer&#x02019;s disease-induced rat brain. BioImpacts: BI 6:203<pub-id pub-id-type="pmid">28265536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Mascitelli</surname><given-names>L</given-names></name><name><surname>Pezzetta</surname><given-names>F</given-names></name></person-group><article-title>Does metformin improve polycystic ovary syndrome symptoms through reduction in body iron stores?</article-title><source>Eur J Endocrinol</source><year>2008</year><volume>158</volume><fpage>439</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1530/eje-07-0801</pub-id><pub-id pub-id-type="pmid">18299480</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Mascitelli L, Pezzetta F (2008) Does metformin improve polycystic ovary syndrome symptoms through reduction in body iron stores? Eur J Endocrinol 158:439&#x02013;439. 10.1530/eje-07-0801<pub-id pub-id-type="pmid">18299480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Matthaei</surname><given-names>S</given-names></name><name><surname>Greten</surname><given-names>H</given-names></name></person-group><article-title>Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane</article-title><source>Diabete &#x00026; Metabolisme</source><year>1991</year><volume>17</volume><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">1718789</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Matthaei S, Greten H (1991) Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. Diabete &#x00026; Metabolisme 17:150&#x02013;158<pub-id pub-id-type="pmid">1718789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Miguel-Hidalgo</surname><given-names>J</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cacabelos</surname><given-names>R</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name></person-group><article-title>Neuroprotection by memantine against neurodegeneration induced by &#x003b2;-amyloid (1&#x02013;40)</article-title><source>Brain Res</source><year>2002</year><volume>958</volume><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)03731-9</pub-id><pub-id pub-id-type="pmid">12468047</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Miguel-Hidalgo J, Alvarez X, Cacabelos R, Quack G (2002) Neuroprotection by memantine against neurodegeneration induced by &#x003b2;-amyloid (1&#x02013;40). Brain Res 958:210&#x02013;221<pub-id pub-id-type="pmid">12468047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>DK</given-names></name><name><surname>Ismail</surname><given-names>CA</given-names></name><name><surname>Ghareeb</surname><given-names>DA</given-names></name></person-group><article-title>Differential metformin dose-dependent effects on cognition in rats: role of Akt</article-title><source>Psychopharmacology</source><year>2016</year><volume>233</volume><fpage>2513</fpage><lpage>2524</lpage><pub-id pub-id-type="doi">10.1007/s00213-016-4301-2</pub-id><pub-id pub-id-type="pmid">27113224</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Mostafa DK, Ismail CA, Ghareeb DA (2016) Differential metformin dose-dependent effects on cognition in rats: role of Akt. Psychopharmacology 233:2513&#x02013;2524<pub-id pub-id-type="pmid">27113224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>A</given-names></name><name><surname>Tupper</surname><given-names>D</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><name><surname>Gilbertson</surname><given-names>D</given-names></name><name><surname>Pederson</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Hochhalter</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Kane</surname><given-names>R</given-names></name></person-group><article-title>Cognitive impairment in hemodialysis patients is common</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000225182.15532.40</pub-id><pub-id pub-id-type="pmid">16864811</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Murray A, Tupper D, Knopman D, Gilbertson D, Pederson S, Li S, Smith G, Hochhalter A, Collins A, Kane R (2006) Cognitive impairment in hemodialysis patients is common. Neurology 67:216&#x02013;223<pub-id pub-id-type="pmid">16864811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Mustafa</surname><given-names>I</given-names></name><name><surname>Anwar</surname><given-names>H</given-names></name><name><surname>Irfan</surname><given-names>S</given-names></name><name><surname>Muzaffar</surname><given-names>H</given-names></name><name><surname>Ijaz</surname><given-names>MU</given-names></name></person-group><article-title>Attenuation of carbohydrate metabolism and lipid profile by methanolic extract of Euphorbia helioscopia and improvement of beta cell function in a type 2 diabetic rat model</article-title><source>BMC Complement Med Ther</source><year>2022</year><volume>22</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s12906-022-03507-2</pub-id><pub-id pub-id-type="pmid">35078449</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Mustafa I, Anwar H, Irfan S, Muzaffar H, Ijaz MU (2022) Attenuation of carbohydrate metabolism and lipid profile by methanolic extract of Euphorbia helioscopia and improvement of beta cell function in a type 2 diabetic rat model. BMC Complement Med Ther 22:23. 10.1186/s12906-022-03507-2<pub-id pub-id-type="pmid">35078449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Niehaus</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Samuelsson</surname><given-names>B</given-names></name></person-group><article-title>Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation</article-title><source>Eur J Biochem</source><year>1968</year><volume>6</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1968.tb00428.x</pub-id><pub-id pub-id-type="pmid">4387188</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Niehaus W Jr, Samuelsson B (1968) Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 6:126&#x02013;130<pub-id pub-id-type="pmid">4387188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikimi</surname><given-names>M</given-names></name><name><surname>Appaji</surname><given-names>N</given-names></name><name><surname>Yagi</surname><given-names>K</given-names></name></person-group><article-title>The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen</article-title><source>Biochem Biophys Res Commun</source><year>1972</year><volume>46</volume><fpage>849</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1016/s0006-291x(72)80218-3</pub-id><pub-id pub-id-type="pmid">4400444</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Nishikimi M, Appaji N, Yagi K (1972) The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Biophys Res Commun 46:849&#x02013;854. 10.1016/s0006-291x(72)80218-3<pub-id pub-id-type="pmid">4400444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Nitsch</surname><given-names>R</given-names></name><name><surname>Hoyer</surname><given-names>S</given-names></name></person-group><article-title>Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex</article-title><source>Neurosci Lett</source><year>1991</year><volume>128</volume><fpage>199</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(91)90260-Z</pub-id><pub-id pub-id-type="pmid">1834965</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Nitsch R, Hoyer S (1991) Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 128:199&#x02013;202. 10.1016/0304-3940(91)90260-Z<pub-id pub-id-type="pmid">1834965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Ormazabal</surname><given-names>V</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Elfeky</surname><given-names>O</given-names></name><name><surname>Aguayo</surname><given-names>C</given-names></name><name><surname>Salomon</surname><given-names>C</given-names></name><name><surname>Zu&#x000f1;iga</surname><given-names>FA</given-names></name></person-group><article-title>Association between insulin resistance and the development of cardiovascular disease</article-title><source>Cardiovasc Diabetol</source><year>2018</year><volume>17</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0762-4</pub-id><pub-id pub-id-type="pmid">30170598</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu&#x000f1;iga FA (2018) Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 17:122. 10.1186/s12933-018-0762-4<pub-id pub-id-type="pmid">30170598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Paglia</surname><given-names>DE</given-names></name><name><surname>Valentine</surname><given-names>WN</given-names></name></person-group><article-title>Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase</article-title><source>J Lab Clin Med</source><year>1967</year><volume>70</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">6066618</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158&#x02013;169<pub-id pub-id-type="pmid">6066618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Percie du Sert</surname><given-names>N</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Avey</surname><given-names>MT</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Howells</surname><given-names>DW</given-names></name><name><surname>Hurst</surname><given-names>V</given-names></name><name><surname>Karp</surname><given-names>NA</given-names></name><name><surname>Lazic</surname><given-names>SE</given-names></name><name><surname>Lidster</surname><given-names>K</given-names></name><name><surname>MacCallum</surname><given-names>CJ</given-names></name><name><surname>Macleod</surname><given-names>M</given-names></name><name><surname>Pearl</surname><given-names>EJ</given-names></name><name><surname>Petersen</surname><given-names>OH</given-names></name><name><surname>Rawle</surname><given-names>F</given-names></name><name><surname>Reynolds</surname><given-names>P</given-names></name><name><surname>Rooney</surname><given-names>K</given-names></name><name><surname>Sena</surname><given-names>ES</given-names></name><name><surname>Silberberg</surname><given-names>SD</given-names></name><name><surname>Steckler</surname><given-names>T</given-names></name><name><surname>W&#x000fc;rbel</surname><given-names>H</given-names></name></person-group><article-title>Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0</article-title><source>PLoS Biol</source><year>2020</year><volume>18</volume><fpage>e3000411</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000411</pub-id><pub-id pub-id-type="pmid">32663221</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, W&#x000fc;rbel H (2020) Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18:e3000411. 10.1371/journal.pbio.3000411<pub-id pub-id-type="pmid">32663221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>RC</given-names></name></person-group><article-title>How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture</article-title><source>Neurology</source><year>2018</year><volume>91</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000006088</pub-id><pub-id pub-id-type="pmid">30089620</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Petersen RC (2018) How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. Neurology 91:395&#x02013;402<pub-id pub-id-type="pmid">30089620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Pilipenko</surname><given-names>V</given-names></name><name><surname>Narbute</surname><given-names>K</given-names></name><name><surname>Pupure</surname><given-names>J</given-names></name><name><surname>Langrate</surname><given-names>IK</given-names></name><name><surname>Muceniece</surname><given-names>R</given-names></name><name><surname>Klu&#x00161;a</surname><given-names>V</given-names></name></person-group><article-title>Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer&#x02019;s disease</article-title><source>Eur J Pharmacol</source><year>2020</year><volume>881</volume><fpage>173290</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173290</pub-id><pub-id pub-id-type="pmid">32580040</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Pilipenko V, Narbute K, Pupure J, Langrate IK, Muceniece R, Klu&#x00161;a V (2020) Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer&#x02019;s disease. Eur J Pharmacol 881:173290. 10.1016/j.ejphar.2020.173290<pub-id pub-id-type="pmid">32580040</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Radwan</surname><given-names>AM</given-names></name><name><surname>Aboelfetoh</surname><given-names>EF</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Mohamed</surname><given-names>TM</given-names></name><name><surname>El-Keiy</surname><given-names>MM</given-names></name></person-group><article-title>Fenugreek-mediated synthesis of zinc oxide nanoparticles and evaluation of its in vitro and in vivo antitumor potency</article-title><source>Biomed Res Ther</source><year>2021</year><volume>8</volume><fpage>4483</fpage><lpage>4496</lpage><pub-id pub-id-type="doi">10.15419/bmrat.v8i8.687</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Radwan AM, Aboelfetoh EF, Kimura T, Mohamed TM, El-Keiy MM (2021) Fenugreek-mediated synthesis of zinc oxide nanoparticles and evaluation of its in vitro and in vivo antitumor potency. Biomed Res Ther 8:4483&#x02013;4496. 10.15419/bmrat.v8i8.687</mixed-citation></citation-alternatives></ref><ref id="CR56"><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>S</given-names></name><name><surname>Pellatt</surname><given-names>LJ</given-names></name><name><surname>Bryan</surname><given-names>SJ</given-names></name><name><surname>Whitehead</surname><given-names>SA</given-names></name><name><surname>Mason</surname><given-names>HD</given-names></name></person-group><article-title>Action of Metformin on the insulin-signaling pathway and on glucose transport in human granulosa cells</article-title><source>J Clin Endocrinol Metabolism</source><year>2011</year><volume>96</volume><fpage>E427</fpage><lpage>E435</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-2060</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Rice S, Pellatt LJ, Bryan SJ, Whitehead SA, Mason HD (2011) Action of Metformin on the insulin-signaling pathway and on glucose transport in human granulosa cells. J Clin Endocrinol Metabolism 96:E427&#x02013;E435. 10.1210/jc.2010-2060</mixed-citation></citation-alternatives></ref><ref id="CR57"><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Rygiel</surname><given-names>K</given-names></name></person-group><article-title>Novel strategies for Alzheimer&#x02019;s disease treatment: an overview of anti-amyloid beta monoclonal antibodies</article-title><source>Indian J Pharmacol</source><year>2016</year><volume>48</volume><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.4103/0253-7613.194867</pub-id><pub-id pub-id-type="pmid">28066098</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Rygiel K (2016) Novel strategies for Alzheimer&#x02019;s disease treatment: an overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol 48:629&#x02013;636. 10.4103/0253-7613.194867<pub-id pub-id-type="pmid">28066098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Saffari</surname><given-names>PM</given-names></name><name><surname>Alijanpour</surname><given-names>S</given-names></name><name><surname>Takzaree</surname><given-names>N</given-names></name><name><surname>Sahebgharani</surname><given-names>M</given-names></name><name><surname>Etemad-Moghadam</surname><given-names>S</given-names></name><name><surname>Noorbakhsh</surname><given-names>F</given-names></name><name><surname>Partoazar</surname><given-names>A</given-names></name></person-group><article-title>Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer&#x02019;s disease model</article-title><source>Life Sci</source><year>2020</year><volume>255</volume><fpage>117861</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117861</pub-id><pub-id pub-id-type="pmid">32473247</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Saffari PM, Alijanpour S, Takzaree N, Sahebgharani M, Etemad-Moghadam S, Noorbakhsh F, Partoazar A (2020) Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer&#x02019;s disease model. Life Sci 255:117861<pub-id pub-id-type="pmid">32473247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Widman</surname><given-names>L</given-names></name><name><surname>Hagstr&#x000f6;m</surname><given-names>H</given-names></name></person-group><article-title>Nonalcoholic fatty liver Disease and Risk of Dementia</article-title><source>Neurology</source><year>2022</year><volume>99</volume><fpage>e574</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000200853</pub-id><pub-id pub-id-type="pmid">35831178</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Shang Y, Widman L, Hagstr&#x000f6;m H (2022) Nonalcoholic fatty liver Disease and Risk of Dementia. Neurology 99:e574. 10.1212/WNL.0000000000200853<pub-id pub-id-type="pmid">35831178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name></person-group><article-title>Bidirectional interactions between diabetes and Alzheimer&#x02019;s disease</article-title><source>Neurochem Int</source><year>2017</year><volume>108</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2017.04.020</pub-id><pub-id pub-id-type="pmid">28551028</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Shinohara M, Sato N (2017) Bidirectional interactions between diabetes and Alzheimer&#x02019;s disease. Neurochem Int 108:296&#x02013;302. 10.1016/j.neuint.2017.04.020<pub-id pub-id-type="pmid">28551028</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><mixed-citation publication-type="other">Solfrizzi V, Scafato E, Custodero C, Loparco F, Ciavarella A, Panza F, Seripa D, Imbimbo BP, Lozupone M, Napoli N (2020) Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimer&#x02019;s &#x00026; Dementia: Transl Res Clinical Interventions 6: e12065</mixed-citation></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnen</surname><given-names>JA</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Brickell</surname><given-names>K</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Woltjer</surname><given-names>R</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name></person-group><article-title>Different patterns of cerebral injury in dementia with or without diabetes</article-title><source>Arch Neurol</source><year>2009</year><volume>66</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2008.579</pub-id><pub-id pub-id-type="pmid">19139294</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66:315&#x02013;322. 10.1001/archneurol.2008.579<pub-id pub-id-type="pmid">19139294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><mixed-citation publication-type="other">Sudakov SK, Alekseeva EV, Nazarova GA, Bashkatova VG (2021) Age-related individual behavioural characteristics of adult wistar rats. Animals (Basel). 11: 10.3390/ani11082282</mixed-citation></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanokashira</surname><given-names>D</given-names></name><name><surname>Kurata</surname><given-names>E</given-names></name><name><surname>Fukuokaya</surname><given-names>W</given-names></name><name><surname>Kawabe</surname><given-names>K</given-names></name><name><surname>Kashiwada</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name></person-group><article-title>Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1</article-title><source>FEBS Open Bio</source><year>2018</year><volume>8</volume><fpage>1104</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.12436</pub-id><pub-id pub-id-type="pmid">29988567</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Tanokashira D, Kurata E, Fukuokaya W, Kawabe K, Kashiwada M, Takeuchi H, Nakazato M, Taguchi A (2018) Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1. FEBS Open Bio 8:1104&#x02013;1118<pub-id pub-id-type="pmid">29988567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Thinnes</surname><given-names>A</given-names></name><name><surname>Westenberger</surname><given-names>M</given-names></name><name><surname>Piechotta</surname><given-names>C</given-names></name><name><surname>Lehto</surname><given-names>A</given-names></name><name><surname>Wirth</surname><given-names>F</given-names></name><name><surname>Lau</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name></person-group><article-title>Cholinergic and metabolic effects of metformin in mouse brain</article-title><source>Brain Res Bull</source><year>2021</year><volume>170</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2021.02.018</pub-id><pub-id pub-id-type="pmid">33617923</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Thinnes A, Westenberger M, Piechotta C, Lehto A, Wirth F, Lau H, Klein J (2021) Cholinergic and metabolic effects of metformin in mouse brain. Brain Res Bull 170:211&#x02013;217<pub-id pub-id-type="pmid">33617923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Tousson</surname><given-names>E</given-names></name><name><surname>Beltagy</surname><given-names>DM</given-names></name><name><surname>El-Gerbed</surname><given-names>MSA</given-names></name><name><surname>Gazia</surname><given-names>MA</given-names></name><name><surname>Akela</surname><given-names>MA</given-names></name></person-group><article-title>The ameliorating role of folic acid in rat hippocampus after propylthiouracil-induced hypothyroidism</article-title><source>Biomed Aging Pathol</source><year>2012</year><volume>2</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.biomag.2012.07.004</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Tousson E, Beltagy DM, El-Gerbed MSA, Gazia MA, Akela MA (2012) The ameliorating role of folic acid in rat hippocampus after propylthiouracil-induced hypothyroidism. Biomed Aging Pathol 2:104&#x02013;110. 10.1016/j.biomag.2012.07.004</mixed-citation></citation-alternatives></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Tzioras</surname><given-names>M</given-names></name><name><surname>McGeachan</surname><given-names>RI</given-names></name><name><surname>Durrant</surname><given-names>CS</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name></person-group><article-title>Synaptic degeneration in Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2023</year><volume>19</volume><fpage>19</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/s41582-022-00749-z</pub-id><pub-id pub-id-type="pmid">36513730</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL (2023) Synaptic degeneration in Alzheimer disease. Nat Rev Neurol 19:19&#x02013;38. 10.1038/s41582-022-00749-z<pub-id pub-id-type="pmid">36513730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Uwishema</surname><given-names>O</given-names></name><name><surname>Mahmoud</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Correia</surname><given-names>IFS</given-names></name><name><surname>Bejjani</surname><given-names>N</given-names></name><name><surname>Alwan</surname><given-names>M</given-names></name><name><surname>Nicholas</surname><given-names>A</given-names></name><name><surname>Oluyemisi</surname><given-names>A</given-names></name><name><surname>Dost</surname><given-names>B</given-names></name></person-group><article-title>Is Alzheimer&#x02019;s disease an infectious neurological disease? A review of the literature</article-title><source>Brain Behav</source><year>2022</year><volume>12</volume><fpage>e2728</fpage><pub-id pub-id-type="doi">10.1002/brb3.2728</pub-id><pub-id pub-id-type="pmid">35879909</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Uwishema O, Mahmoud A, Sun J, Correia IFS, Bejjani N, Alwan M, Nicholas A, Oluyemisi A, Dost B (2022) Is Alzheimer&#x02019;s disease an infectious neurological disease? A review of the literature. Brain Behav 12:e2728. 10.1002/brb3.2728<pub-id pub-id-type="pmid">35879909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><mixed-citation publication-type="other">Verma N, Velmurugan GV, Winford E, Coburn H, Kotiya D, Leibold N, Radulescu L, Despa S, Chen KC, Van Eldik LJ, Nelson PT, Wilcock DM, Jicha GA, Stowe AM, Goldstein LB, Powel DK, Walton JH, Navedo MF, Nystoriak MA, Murray AJ, Biessels GJ, Troakes C, Zetterberg H, Hardy J, Lashley T, Despa F (2023) A&#x003b2; efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas. Commun Biol 6(2). 10.1038/s42003-022-04398-2</mixed-citation></ref><ref id="CR70"><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Sano</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Mano</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Matsuo</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name></person-group><article-title>Differential effects of diet-and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Mol Neurodegeneration</source><year>2019</year><volume>14</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1186/s13024-019-0315-7</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wakabayashi T, Yamaguchi K, Matsui K, Sano T, Kubota T, Hashimoto T, Mano A, Yamada K, Matsuo Y, Kubota N (2019) Differential effects of diet-and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer&#x02019;s disease. Mol Neurodegeneration 14:1&#x02013;18</mixed-citation></citation-alternatives></ref><ref id="CR71"><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Sui</surname><given-names>D</given-names></name></person-group><article-title>Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes</article-title><source>Exp Ther Med</source><year>2017</year><volume>14</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.3892/etm.2017.4475</pub-id><pub-id pub-id-type="pmid">28672943</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Zhang S, Xu H, Yu X, Wu Y, Sui D (2017) Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med 14:383&#x02013;390<pub-id pub-id-type="pmid">28672943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>NQ</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>SY</given-names></name><name><surname>Shi</surname><given-names>JS</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name></person-group><article-title>Diabetes mellitus and Alzheimer&#x02019;s disease: GSK-3&#x003b2; as a potential link</article-title><source>Behav Brain Res</source><year>2018</year><volume>339</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2017.11.015</pub-id><pub-id pub-id-type="pmid">29158110</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Zhang Y, Huang NQ, Yan F, Jin H, Zhou SY, Shi JS, Jin F (2018) Diabetes mellitus and Alzheimer&#x02019;s disease: GSK-3&#x003b2; as a potential link. Behav Brain Res 339:57&#x02013;65. 10.1016/j.bbr.2017.11.015<pub-id pub-id-type="pmid">29158110</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>